Exploring the Diversity and Predictors of Histopathological Findings Across the European Association of Urology Guidelines Office Rapid Reaction Group Priority Groups for Patients with Renal Tumors: Implications for Individualized Prioritization of Renal Cancer Care.
COVID-19
Histology
Nephrectomy
Prioritization
Renal cancer
Journal
European urology open science
ISSN: 2666-1683
Titre abrégé: Eur Urol Open Sci
Pays: Netherlands
ID NLM: 101771568
Informations de publication
Date de publication:
Dec 2021
Dec 2021
Historique:
accepted:
24
09
2021
entrez:
11
11
2021
pubmed:
12
11
2021
medline:
12
11
2021
Statut:
epublish
Résumé
In response to the COVID-19 pandemic, the European Association of Urology (EAU) Guidelines Office Rapid Reaction Group (GORRG) defined priority groups to guide the prioritization of surgery for nonmetastatic renal cell carcinoma (RCC). In this study we explored the diversity and predictors of histopathological findings across the EAU GORRG priority groups using a large database of 1734 consecutive patients undergoing elective surgery for nonmetastatic renal masses between 2017 and 2020 at a referral institution. Overall, 940 (54.2%), 358 (20.6%), and 436 (25.2%) patients were classified as low-, intermediate-, and high-priority, respectively. The low-, intermediate-, and high-risk groups significantly differed regarding all primary histopathological outcomes: benign histology (21.6% vs 15.9% vs 6.4%; During the COVID-19 pandemic, the European Association of Urology designed a scheme to prioritize patients needing surgery for kidney cancer according to their tumor characteristics and symptoms. We used results from our hospital database to test the scheme and found that the priority classification can be used to predict cancer outcomes after surgery. This scheme may be useful in prioritizing kidney cancer surgeries after the COVID-19 pandemic.
Identifiants
pubmed: 34761237
doi: 10.1016/j.euros.2021.09.009
pii: S2666-1683(21)01688-8
pmc: PMC8567362
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5-9Informations de copyright
© 2021 The Author(s).
Références
Eur Urol. 2021 Aug;80(2):265-267
pubmed: 34024653
Eur Urol Focus. 2020 Sep 15;6(5):1032-1048
pubmed: 32553544
Eur Urol Focus. 2020 Jul 14;:
pubmed: 32680829
Eur Urol. 2020 Nov;78(5):731-742
pubmed: 32893062
Eur Urol. 2020 Jul;78(1):29-42
pubmed: 32414626
Urology. 2021 Jan;147:21-26
pubmed: 32979378
Eur Urol Oncol. 2021 Feb;4(1):22-41
pubmed: 33408053
BMC Med. 2019 Oct 3;17(1):182
pubmed: 31578141
Eur Urol. 2018 May;73(5):772-780
pubmed: 29398265
Eur Urol. 2020 Jul;78(1):21-28
pubmed: 32376137
Cancer. 2003 Apr 1;97(7):1663-71
pubmed: 12655523
Eur Urol. 2021 Nov;80(5):575-588
pubmed: 33558091
BJU Int. 2021 Aug;128(2):131-143
pubmed: 34060192